MannKind jumps following Phase III results for
diabetes drug
- MannKind (MNKD) surges 13% after saying that its Afrezza treatment for Type 1 and 2 diabetes was more effective than insulin and oral therapies in two Phase III trials.
- The results include a lowering of fasting blood glucose levels and fewer incidences of hypoglycemia.
- MannKind expects to submit the trial data to the FDA in Q4.
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/